7 stories about Ajovy
קור שולץ מנכ"ל טבע 9.11.19

Teva Receives FDA Approval for Migraine Autoinjector

29.01.20|Sophie Shulman
Teva’s anti-migraine injection was approved in late 2018 but struggled to establish a market share due to both Amgen and Eli Lilly offering a similar drug with an autoinjector
אתר טבע כפר סבא

Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing

17.11.19|Navit Zomer
The Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
אתר טבע כפר סבא

Teva Discontinues Development of Cluster Headache Drug

24.04.19|Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Market Indifferent to European Approval of Teva's Migraine Drug

02.04.19|Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
מנכ"ל טבע החדש קור שולץ 2

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports

27.01.19|Lilach Baumer
In October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
קאר שולץ מנכל טבע

Teva Shares Rise Following FDA Approval of Migraine Drug

16.09.18|Dror Reich
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually